Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative intravitreal triamcinolone in phacoemulsification for diabetic macular oedema
2006-005400-14Phase 4Terminated
- Sponsor
- Moorfields Eye Hospital
- Start
- Oct 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of triamcinolone in diabetic macular edema (DME), diabetes mellitus type 1 (T1D), type 2 diabetes mellitus (T2DM) and 1 more, sponsored by Moorfields Eye Hospital. Primary endpoint: Resolution of clinically significant macular oedema at 12 months. Started Oct 2006; status: terminated.
02
Drugs
triamcinolone
03
Conditions
diabetic macular edema (DME)diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)cataract
Beyond the preview
Go deeper on 2006-005400-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005400-14.